期刊文献+

左旋多巴诱发异动症6-羟基多巴帕金森病大鼠模型的建立及行为学评价 被引量:3

Establishment and Evaluation of the Behavior of the Parkinson′s Disease Rat Model of Levodopa Induced Dyskinesias
原文传递
导出
摘要 目的应用左旋多巴(L-DOPA)建立帕金森病(PD)大鼠异动症模型,对其行为学进行评价。方法对25只SD大鼠右内侧前脑束注射6-羟基多巴(6-OHDA)建立PD大鼠模型,两周后行阿朴吗啡(1mg/kg)皮下注射,将成功PD大鼠模型随机分成两组,分别予生理盐水(NS)45mg/kg和L-DOPA(25mg/kg+6.25mg/kg苄丝肼)腹腔注射,2次/d,共治疗21d,在治疗第2、9、11、18、21d进行前肢功能测定、异常不自主运动(AIM)评分和旋转反应时间测定。结果 20只建模成功的PD大鼠模型中,10只给以生理盐水(NS)治疗,另10只给以L-DOPA治疗。NS组治疗前后前肢跨步数无明显差异(P>0.05),治疗期间始终未出现AIM;L-DOPA治疗组后前肢跨步数较治疗前显著增加(P<0.01),8只出现不同程度的AIM表现,并随治疗时间的延长,AIM评分逐渐升高,第21dAIM总分较第2d增加(P<0.05),旋转反应时间随治疗时间的延长而缩短,第18、21d和第2d相比,显著缩短(P<0.05)。结论 L-DOPA诱发6-OHDA的PD大鼠AIM与PD患者服用美多巴出现的异动症某些方面相似,为研究异动症提供了理想的模型。 Objective To establish the Parkinson’s disease (PD) rat model of the levodopa induced dyskinesia (LID) with the application of L-DOPA and 6-OHDA and to evaluate their behavioral characteristics.Methods The hemi-parkinsonian rat model was produced by stereotaxically injecting 6-OHDA to right medial forebrain bundle (MFB).Two weeks later,apomorphine-induced rotation test was performed to examine the rat model of PD.Animals were intraperitoneally treated by NS(45mg/kg) and L-DOPA (25mg/kg+6.25 mg/kg benserazide) respectively twice daily for 21 days.On the 2nd day,9th day,11th day,18th day,the 21st day during the treatment,forepaw adjusting steps and AIM and rotational duration were respectively observed.The quality of AIM was estimated by using the rat AIM rating scale.Results Twenty successful rat PD models,ten of whom were given NS treatment,while the other ten L-DOPA treatment.Contralateral forepaw performance was significantly improved after levodopa treatment,not NS treatment,but gradually reduced with more and more severe AIM following repeated levodopa therapy.The treatment of levodopa gradually induced abnormal involuntary movement(AIM) and the score of AIM gradually increased.Rotation duration was shortened significantly.On the 21st day,the AIM Score increased compared to the 2nd day.Rotation duration was shortened significantly.Conclusion Levodopa·induced rat AIM model of PD is similar to that with the levodopa-induced dyskinesia (LID) in PD patients,which provides an ideal model for LID study.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2010年第2期236-239,共4页 Suzhou University Journal of Medical Science
基金 江苏省"六大人才高峰"项目(07-B-005) 苏州大学科技创新培育工程重大项目
关键词 帕金森病 左旋多巴 异常不自主运动 异动症 SD大鼠 Parkinson’s disease levodopa abnormal involuntary movement dyskinesia SD rats
  • 相关文献

参考文献11

  • 1Linazasoro G. New ideas on the origin of L-dopa-indueed dyskinesias: age, genes and neural plasticity [ J ]. Trends Pharmacol Sci, 2005,26 ( 8 ) : 391 - 397.
  • 2Santini E, Valjent E, Fisone G. Parkinson's disease: Levodopa-induced dyskinesia and signal transduction~[J].FEBS J, 2008,275(7) : 1392 - 1399.
  • 3包新民 舒斯云.大鼠脑立体定向图谱[M].北京:人民卫生出版社,1991.48-60.
  • 4罗蔚锋,包仕尧,刘春风,霍红梅,张志琳,韩旺,吴冠会.内侧前脑束不同部位注射6-羟多巴胺建立帕金森病大鼠模型的对比性研究[J].苏州大学学报(医学版),2007,27(1):66-68. 被引量:6
  • 5Chang JW, Wachtel SR, Young D, et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease : studies on medial forebrain bundle and striatal lesions [ J ]. Neuroscience, 1999, 88 (2) :617 -628.
  • 6董玉林,张志军,郁晓燕,倪衡建.MPTP诱导的小鼠PD模型中相关脑区TNF-α的表达变化[J].苏州大学学报(医学版),2009,29(1):46-49. 被引量:2
  • 7Lee CS, Cenci MA, Schulzer M, et al. Embryonic ventral mesence phalic grafts improve levod opa-induced dyskinesia in a rat model of Parkinson's disease[ J]. Brain ,2000, 123(pt7) :1365 - 1379.
  • 8Bove J, Marin C, Bonastre M,et al. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats [ J ]. Synapse, 2002,46 ( 4 ) : 251 - 257.
  • 9Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease [ J ]. Exp Neurol, 2003,184( 1 ) :285 - 294.
  • 10Hauser RA. Levodopa: past, present, and future[ J]. Eur Neurol, 2009,62 ( 1 ) : 1 - 8.

二级参考文献18

  • 1陈生弟,王刚.帕金森病的实验研究进展[J].中华老年医学杂志,2004,23(7):447-449. 被引量:11
  • 2Fornai F, Lenzi P, C, esi M, et al. Recent knowledge on molecular components of lewy bodies discloses future therapeutic strategies in Parkinson's disease[J]. Curt Drug Targets CNS Neurol Disord, 2003, 2(3): 149-152.
  • 3Sriram K, Matheson JM, Benkovic SA, et al. Mice deficient in TNF receptors are protected against dopaminergic neu-rotoxicity: implications for Parkinson' s disease[J]. FASEB J, 2002, 16(11):1474-1476.
  • 4Sriram K, Matheson JM, Benkovic SA, et al. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neuro-toxicity: role of TNF-alpha[J]. FASEB J, 2006, 20(6):670- 682.
  • 5Ferger B, Leng A, Mura A, et al. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum[J]. J Neuroehem, 2004, 89(4):822-833.
  • 6Mosley RL, Benner EJ, Kadiu I, et al. Neuroinflammation,oxidative stress and the pathogenesis of parkinson's disease[J]. Clin Neurosei Res, 2006, 6(5):261-281.
  • 7Mogi M, Harada M, Riederer P, et al. Tumor necrosis fac-tor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients[J]. Neurosci Lett, 1994, 165(1-2):208-210.
  • 8Leng A, Mum A, Feldon J, et al. Tumor necrosis factor-M-pha receptor ablation in a chronic MPTP mouse model of Parkinson's disease[J]. Neurosci Lett, 2005, 375(2):107- 111.
  • 9Zhao C, Ling Z, Newman MB, et al. TNF-alpha knockout andminocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice[J]. Neurobiol Dis, 2007, 26 (1):36-46.
  • 10包新民 舒斯云.大鼠脑立体定向图谱[M].北京:人民卫生出版社,1991.48-60.

共引文献77

同被引文献25

  • 1Xue-Bing CAO Qiang GUAN Yan XU Lan WANG Sheng-Gang SUN.Mechanism of over-activation in direct pathway mediated by dopamine D_1 receptor in rats with levodopa-induced dyskinesias[J].Neuroscience Bulletin,2006,22(3):159-164. 被引量:9
  • 2巴茂文,刘振国,孔敏,杨红旗,陈生弟,陆国强.左旋多巴诱发帕金森病大鼠异动症模型的建立和评价[J].上海交通大学学报(医学版),2006,26(7):810-812. 被引量:15
  • 3LeWitt PA,Ondo WG,Van Lunen B.Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injec-tions in treating"off"episodes in advanced Parkinson disease[].Clinical Neuropharmacology.2009
  • 4Eden T,Beverly DL,Helen D,et al.Acrylamide decreased dopa-mine levels and increased 3-nitrotyrosine(3-NT)levels in PC 12cells[].Neuroscience Letters.2009
  • 5Schapira AH,Emre M,Jenner P,et al.Levodopa in the treatment of Parkinson’’s disease[].European Journal of Neurology.2009
  • 6Padovan-Neto FE,Echeverry MB,Tumas V,et al.Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson’’s disease[].Neuroscience.2009
  • 7LeWitt PA,Ondo WG,Van Lunen B.Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injec-tions in treating"off"episodes in advanced Parkinson disease[].Clinical Neuropharmacology.2009
  • 8Eden T,Beverly DL,Helen D,et al.Acrylamide decreased dopa-mine levels and increased 3-nitrotyrosine(3-NT)levels in PC 12cells[].Neuroscience Letters.2009
  • 9Padovan-Neto FE,Echeverry MB,Tumas V,et al.Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson’’s disease[].Neuroscience.2009
  • 10Schapira AH,Emre M,Jenner P,et al.Levodopa in the treatment of Parkinson’’s disease[].European Journal of Neurology.2009

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部